P
Peter V. Finn
Researcher at Brigham and Women's Hospital
Publications - 45
Citations - 5867
Peter V. Finn is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Heart failure & Myocardial infarction. The author has an hindex of 21, co-authored 44 publications receiving 5575 citations. Previous affiliations of Peter V. Finn include Harvard University.
Papers
More filters
Journal ArticleDOI
Cardiovascular Risk Associated With Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention
Scott D. Solomon,John J.V. McMurray,Marc A. Pfeffer,Janet Wittes,Robert A. Fowler,Peter V. Finn,William F. Anderson,Ann G. Zauber,Ernest T. Hawk,Monica M. Bertagnolli +9 more
TL;DR: Celecoxib use was associated with a dose-related increase in the composite end point of death from cardiovascular causes, myocardial infarction, stroke, or heart failure, providing further evidence that the use of COX-2 inhibitors may increase the risk of serious cardiovascular events.
Journal ArticleDOI
Survival after an experimental myocardial infarction: beneficial effects of long-term therapy with captopril.
TL;DR: In this experimental preparation of myocardial infarction and left ventricular dysfunction, survival was inversely related to size ofinfarction.
Journal ArticleDOI
Sudden Death in Patients with Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or Both
Scott D. Solomon,Steve Zelenkofske,John J.V. McMurray,Peter V. Finn,Eric J. Velazquez,George Ertl,Adam Harsanyi,Jean L. Rouleau,Aldo P. Maggioni,Lars Køber,Harvey D. White,Frans Van de Werf,Karen S. Pieper,Robert M. Califf,Marc A. Pfeffer +14 more
TL;DR: The risk of sudden death is highest in the first 30 days after myocardial infarction among patients with left ventricular dysfunction, heart failure, or both, and earlier implementation of strategies for preventing sudden death may be warranted in selected patients.
Journal ArticleDOI
Cardiovascular Risk of Celecoxib in 6 Randomized Placebo-Controlled Trials: The Cross Trial Safety Analysis
Scott D. Solomon,Janet Wittes,Peter V. Finn,Robert A. Fowler,Jaye L. Viner,Monica M. Bertagnolli,Nadir Arber,Bernard Levin,Curtis L. Meinert,Barbara K. Martin,Joseph L. Pater,Paul E. Goss,Peter Lance,Stefanie Obara,Emily Y. Chew,Jonghyeon Kim,Gretchen Arndt,Ernest T. Hawk +17 more
TL;DR: Evidence of differential cardiovascular risk as a function of celecoxib dose regimen and baseline cardiovascular risk is observed and may help guide treatment decisions for patients who derive clinical benefit from selective cyclooxygenase-2 inhibition.
Journal ArticleDOI
Body Mass Index and Prognosis in Patients With Chronic Heart Failure Insights From the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) Program
Satish Kenchaiah,Stuart J. Pocock,Duolao Wang,Peter V. Finn,Leonardo A. M. Zornoff,Hicham Skali,Marc A. Pfeffer,Salim Yusuf,Karl Swedberg,Eric L. Michelson,Christopher B. Granger,John J.V. McMurray,Scott D. Solomon +12 more
TL;DR: In patients with symptomatic heart failure and either reduced or preserved left ventricular systolic function, underweight or low BMI was associated with increased mortality, primarily in patients without evidence of fluid overload (edema).